A Phase 3 interventional study of Romiplostim in Thrombocytopenia in Pediatric Subjects With Immune Idiopathic Thrombocytopenic Purpura ITP, sponsored by Amgen. Completed at 31 sites in 4 countries. Open to participants aged 1 Year and older. Per ClinicalTrials.gov, last updated 2020-01-18.
Sponsored by Amgen · Phase 3, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic — 5 open to participants now, 6 under way, 2 of them phase 3. romiplostim · Purpura, Thrombocytopenic, Idiopathic.
Among the 29 studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic, this one is the 13th largest by enrollment, is one of 3 that started in 2009, is one of 13 in phase 3, and was the 12th registered.
504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.
Browse Purpura, Thrombocytopenic, Idiopathic studies →5 of the 29 studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic are open now, in 3 countries. Recruiting first, the newest first:
Amgen · Sites in United States
Ages 18–100
The First Affiliated Hospital of Soochow University · Sites in China
Ages 18+
The First Affiliated Hospital of Soochow University · Sites in China
Ages 14+
Wuhan Union Hospital, China · Sites in China
Ages 18–75
Nahda University · Sites in Egypt
Ages 18–65
By country, each count listing its studies:
romiplostim: first FDA approval 2008 (NPLATE), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.
This study: 1 Year and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 11 · Phase 3 13 · Phase 4 3
First in 2002; this study’s year is marked. 3 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 66 is above the median of 58 across 377 interventional studies indexed under Purpura, Thrombocytopenic, Idiopathic.
Median enrollment 62 across the 29 interventional studies. Of the 20 that completed or were terminated, 12 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 29 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
18 studies in Purpura, Thrombocytopenic, Idiopathic by Amgen: 1 open now, 1 under way, 1 of them phase 3. Of 17 finished, 13 (76%) have results posted.
Among the 18 studies in Purpura, Thrombocytopenic, Idiopathic by Amgen, this one is the 8th largest by enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2009, is one of 10 in phase 3, and was the 13th registered.
Amgen’s Purpura, Thrombocytopenic, Idiopathic studies by the year they started, since 2002.
2 of the studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07206823The First Affiliated Hospital of Soochow UniversityEfficacy and Safety of Romiplostim N01 Combined With Rituximab in Patients With Oral TPO-RA-Refractory Primary Immune Thrombocytopenia | 2027-02-28 |
| NCT07612319The First Affiliated Hospital of Soochow UniversityRomiplostim for Oral TPO-RA Resistant ITP | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 29 studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Amgen’s 18 in Purpura, Thrombocytopenic, Idiopathic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is an extension study designed to assess the safety and durability of platelet count increases with romiplostim treatment of thrombocytopenic patients with immune (Idiopathic) thrombocytopenia purpura. This study is available to pediatric patients who have completed a previous romiplostim ITP study and meet the eligibility criteria of this study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received romiplostim administered by subcutaneous injection once a week. The starting dose of romiplostim was 1 μg/kg; weekly dose increases continued in increments of 1 μg/kg/week to a maximum dose of 10 μg/kg in an attempt to reach a target platelet count of between 50 x 10\^9/L and 200 x 10\^9/L.
Biological: Romiplostim
Administered by subcutaneous injection once a week.
Also known as: Nplate
Number of Participants With Adverse Events
The adverse event (AE) severity grading scale used was the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 grading scale, where Grade 1 = Mild AE; Grade 2 = Moderate AE; Grade 3 = Severe AE; Grade 4 = Life-threatening or disabling AE; Grade 5 = Death related to AE. A serious adverse event was defined as an adverse event that met at least one of the following serious criteria: * fatal * life threatening (places the subject at immediate risk of death) * required in-patient hospitalization or prolongation of existing hospitalization * resulted in persistent or significant disability/incapacity * congenital anomaly/birth defect * other medically important serious event. The investigator assessed whether each adverse event was possibly related to the investigational product.
Time frame: From first dose of study drug until 1 week after last dose. The median (minimum, maximum) duration of treatment was 135.0 weeks (5, 363 weeks).
Duration Adjusted Rate of Treatment Emergent Adverse Events
Exposure adjusted rate was defined as the total number of events divided by the duration of time participants were under observation. The adverse event (AE) severity grading scale used was the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 grading scale, where Grade 1 = Mild AE; Grade 2 = Moderate AE; Grade 3 = Severe AE; Grade 4 = Life-threatening or disabling AE; Grade 5 = Death related to AE. A serious adverse event was defined as an adverse event that met at least one of the following serious criteria: * fatal * life threatening (places the subject at immediate risk of death) * required in-patient hospitalization or prolongation of existing hospitalization * resulted in persistent or significant disability/incapacity * congenital anomaly/birth defect * other medically important serious event. The investigator assessed whether each adverse event was possibly related to the study drug.
Time frame: From first dose of study drug until 1 week after last dose. The median (minimum, maximum) duration of treatment was 135.0 weeks (5, 363 weeks).
Number of Participants Who Developed Antibodies to Romiplostim
Two validated assays were used to test for antibodies to romiplostim / the thrombopoietin-mimetic peptide component of romiplostim (TMP). The first was an immunoassay to confirm the presence of antibodies. The second was a cell-based bioassay to detect neutralizing or inhibitory effects in vitro. If a sample was positive in both assays, a participant was defined as positive for neutralizing antibodies. Transient antibodies are those positive post-baseline but negative at the last time point tested. Persistent antibodies were those positive at the last time point tested.
Time frame: Once a year until the end of treatment and 1 week after the end of treatment; median (minimim, maximum) time on study was 34 (2, 91) months.
Number of Participants Who Developed Antibodies to Endogenous Thrombopoietin
Two validated assays were used to test for antibodies to endogenous thrombopoietin (TPO). The first was an immunoassay to confirm the presence of antibodies. The second was a cell-based bioassay to detect neutralizing or inhibitory effects in vitro. If a sample was positive in both assays, a participant was defined as positive for neutralizing antibodies. Transient antibodies are those positive post-baseline but negative at the last time point tested. Persistent antibodies were those positive at the last time point tested.
Time frame: Once a year until the end of treatment and 1 week after the end of treatment; median (minimim, maximum) time on study was 34 (2, 91) months.
Percentage of Participants With a Platelet Response
Platelet response was defined as at least one platelet count ≥ 50 x 10\^9/L in the absence of rescue medication during the study.
Time frame: Assessed every 4 weeks for the duration of treatment; the median (minimum, maximum) duration of treatment was 135.0 weeks (5, 363 weeks).
Percentage of Participants Who Used Concomitant ITP Therapy
Time frame: From baseline to the end of treatment; the median (minimum, maximum) duration of treatment was 135.0 weeks (5, 363 weeks).
This study was conducted at 28 centers in Australia, Canada, Spain, and the United States. Participants were enrolled from 30 December 2009 until 19 February 2015.
| Milestone | Romiplostim |
|---|---|
| Started | 66 |
| Received treatment | 65 |
| Completed | 39 |
| Not completed | 27 |
| Withdrew: Noncompliance | 4 |
| Withdrew: Adverse event | 1 |
| Withdrew: Withdrawal by subject | 11 |
| Withdrew: Requirement for alternative therapy | 5 |
| Withdrew: Administrative decision | 5 |
| Withdrew: Protocol specified criteria | 1 |
The adverse event (AE) severity grading scale used was the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 grading scale, where Grade 1 = Mild AE; Grade 2 = Moderate AE; Grade 3 = Severe AE; Grade 4 = Life-threatening or disabling AE; Grade 5 = Death related to AE. A serious adverse event was defined as an adverse event that met at least one of the following serious criteria: * fatal * life threatening (places the subject at immediate risk of death) * required in-patient hospitalization or prolongation of existing hospitalization * resulted in persistent or significant disability/incapacity * congenital anomaly/birth defect * other medically important serious event. The investigator assessed whether each adverse event was possibly related to the investigational product.
| Participants | Romiplostim |
|---|---|
| All adverse events (AEs) | 64 |
| Serious adverse events | 19 |
| AEs leading to discontinuation of study drug | 2 |
| AEs leading to withdrawal from study | 1 |
| Grade 3 adverse events | 21 |
| Grade 4 adverse events | 5 |
| Grade 5 adverse events | 0 |
| Treatment-related adverse events (TRAEs) | 17 |
| Treatment-related serious adverse events | 1 |
| TRAEs leading to discontinuation of study drug | 0 |
| TRAEs leading to withdrawal from study | 0 |
| Grade 3 treatment-related adverse events | 3 |
| Grade 4 treatment-related adverse events | 1 |
| Grade 5 treatment-related adverse events | 0 |
Exposure adjusted rate was defined as the total number of events divided by the duration of time participants were under observation. The adverse event (AE) severity grading scale used was the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 grading scale, where Grade 1 = Mild AE; Grade 2 = Moderate AE; Grade 3 = Severe AE; Grade 4 = Life-threatening or disabling AE; Grade 5 = Death related to AE. A serious adverse event was defined as an adverse event that met at least one of the following serious criteria: * fatal * life threatening (places the subject at immediate risk of death) * required in-patient hospitalization or prolongation of existing hospitalization * resulted in persistent or significant disability/incapacity * congenital anomaly/birth defect * other medically important serious event. The investigator assessed whether each adverse event was possibly related to the study drug.
| events per 100 subject-years | Romiplostim |
|---|---|
| All adverse events (AEs) | 1397.2 |
| Serious adverse events | 29.7 |
| AEs leading to discontinuation of study drug | 2.8 |
| AEs leading to withdrawal from study | 0.6 |
| Grade 3 adverse events | 38.5 |
| Grade 4 adverse events | 6.6 |
| Grade 5 adverse events | 0.0 |
| Treatment-related adverse events (TRAEs) | 24.2 |
| Serious treatment-related adverse events | 1.7 |
| TRAEs leading to discontinuation of study drug | 0.0 |
| TRAEs leading to withdrawal from study | 0.0 |
| Grade 3 treatment-related adverse events | 2.8 |
| Grade 4 treatment-related adverse events | 0.6 |
| Grade 5 treatment-related adverse events | 0.0 |
Two validated assays were used to test for antibodies to romiplostim / the thrombopoietin-mimetic peptide component of romiplostim (TMP). The first was an immunoassay to confirm the presence of antibodies. The second was a cell-based bioassay to detect neutralizing or inhibitory effects in vitro. If a sample was positive in both assays, a participant was defined as positive for neutralizing antibodies. Transient antibodies are those positive post-baseline but negative at the last time point tested. Persistent antibodies were those positive at the last time point tested.
| Participants | Romiplostim |
|---|---|
| Binding antibodies to romiplostim | 5 |
| Transient binding antibodies to romiplostim | 4 |
| Persistent binding antibodies to romiplostim | 1 |
| Neutralizing antibodies to romiplostim | 1 |
| Transient neutralizing antibodies to romiplostim | 0 |
| Persistent neutralizing antibodies to romiplostim | 1 |
Two validated assays were used to test for antibodies to endogenous thrombopoietin (TPO). The first was an immunoassay to confirm the presence of antibodies. The second was a cell-based bioassay to detect neutralizing or inhibitory effects in vitro. If a sample was positive in both assays, a participant was defined as positive for neutralizing antibodies. Transient antibodies are those positive post-baseline but negative at the last time point tested. Persistent antibodies were those positive at the last time point tested.
| Participants | Romiplostim |
|---|---|
| Binding antibodies to TPO | 2 |
| Transient binding antibodies to TPO | 2 |
| Persistent binding antibodies to TPO | 0 |
| Neutralizing antibodies to TPO | 0 |
| Transient neutralizing antibodies to TPO | 0 |
| Persistent neutralizing antibodies to TPO | 0 |
Platelet response was defined as at least one platelet count ≥ 50 x 10\^9/L in the absence of rescue medication during the study.
| percentage of participants | Romiplostim |
|---|---|
| Percentage of Participants With a Platelet Response | 93.8 ± 85.0 |
| percentage of participants | Romiplostim |
|---|---|
| Percentage of Participants Who Used Concomitant ITP Therapy | 47.7 ± 35.1 |
Collected over From first dose of study drug until 1 week after last dose. The median (minimum, maximum) duration of treatment was 135.0 weeks (5, 363 weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Romiplostim | 0/65 (0%) | 19/65 (29.2%) | 64/65 (98.5%) |
| Event | Romiplostim |
|---|---|
| ThrombocytopeniaBlood and lymphatic system disorders | 4/65 |
| PyrexiaGeneral disorders | 3/65 |
| VomitingGastrointestinal disorders | 2/65 |
| HeadacheNervous system disorders | 2/65 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 2/65 |
| AnaemiaBlood and lymphatic system disorders | 1/65 |
| Febrile neutropeniaBlood and lymphatic system disorders | 1/65 |
| Immune thrombocytopenic purpuraBlood and lymphatic system disorders | 1/65 |
| LeukopeniaBlood and lymphatic system disorders | 1/65 |
| Mouth haemorrhageGastrointestinal disorders | 1/65 |
| Event | Romiplostim |
|---|---|
| HeadacheNervous system disorders | 38/65 |
| VomitingGastrointestinal disorders | 32/65 |
| Upper respiratory tract infectionInfections and infestations | 32/65 |
| ContusionInjury, poisoning and procedural complications | 32/65 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 31/65 |
| CoughRespiratory, thoracic and mediastinal disorders | 30/65 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 30/65 |
| PyrexiaGeneral disorders | 28/65 |
| NauseaGastrointestinal disorders | 24/65 |
| NasopharyngitisInfections and infestations | 22/65 |
| Age, Continuous(years) | Overall Study |
|---|---|
| Mean | 10.3 ± 4.2 |
| Age, Customized(Participants) | Overall Study |
|---|---|
| Children (2-11 years) | 37 |
| Adolescents (12-17 years) | 28 |
| Adults (18-64 years) | 1 |
| Sex: Female, Male(Participants) | Overall Study |
|---|---|
| Female | 37 |
| Male | 29 |
| Race(Participants) | Overall Study |
|---|---|
| White or Caucasian | 40 |
| Black or African American | 9 |
| Hispanic or Latino | 9 |
| Asian | 6 |
| Japanese | 0 |
| American Indian or Alaska Native | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Aborigine | 0 |
| Other | 2 |
Ran from Dec 2009 to primary completion in Jan 2017, 84 months.
Results were first posted in Jan 2019, 2 years after primary completion. A results delay was requested in Jul 2017.
Of 41 industry-sponsored phase 3 interventional studies under Purpura, Thrombocytopenic, Idiopathic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 44. This study's 84 months is above that.
Counting every sponsor, half of 57 studies reached it within 28 months; a quarter within 22 and three quarters within 49.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Romiplostim
Purpura, Thrombocytopenic, Idiopathic →